A step toward more accurate dosing for mercaptopurine in childhood acute lymphoblastic leukemia

Journal of Clinical Pharmacology

Volumn 52, Issue 10, 2012, Pages 1610-1613

  Mulla, Hussain ^a   Leary, Andrew ^b   White, Peter ^c   Pandya, Hitesh C ^d  

^a UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^b Shandon Clinic Cork Ireland   (Ireland)

^c Nova Laboratories Limited   (United Kingdom)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

ALL; bioequivalence; children; liquid; mercaptopurine

Indexed keywords

MERCAPTOPURINE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE;

ACCURACY; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD ANALYSIS; BLOOD PRESSURE; BLOOD SAMPLING; BODY MASS; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

6-MERCAPTOPURINE; ADOLESCENT; ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; HUMANS; METHYLTRANSFERASES; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SUSPENSIONS; TABLETS; YOUNG ADULT;

EID: 84870454466     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011423663     Document Type: Article

References (11)

1. Conroy S. Association between licence status and medication errors. Arch Dis Child. 2011 ; 96 (3). 305-306
2. Assessment of the Paediatric Needs: Chemotherapy Products (Part I). London: European Medicines Agency ; 2006 :
3. Questions & Answers: Positions on Specific Questions Addressed to the Pharmacokinetics Working Party. London: European Medicines Agency ; 2011 :
4. Lafolie P, Hayder S, Björk O, Peterson C. Intraindividual variation in 6-mercaptopurine pharmacokinetics during oral maintenance therapy of children with acute lymphoblastic leukaemia. Eur J Clin Pharmacol. 1991 ; 40 (6). 599-601
5. Ford LT, Berg JD. Determination of thiopurine S-methyltransferase activity in erythrocytes using 6-thioguanine as substrate and a non-extraction liquid chromatographic technique. J Chromatogr B Analyt Tecnol Biom Life Sci. 2003 ; 798: 111-115
6. Note for Guidance on the Investigation of Bioavailability and Bioequivalence. London: European Medicines Agency ; 2008 :
7. Lennard L, Keen D, Lilleyman JS. Oral 6-mercaptopurine in childhood leukaemia: parent drug pharmacokinetics and active metabolite concentrations. Clin Pharmacol Ther. 1986 ; 40: 287-292
8. Buckham J, Khalid T, Ballantine N, Holden V, Mycroft J. Why the current situation doubly disadvantages children with cancer. Pharm J. 2004 ; 273: 416
9. Breitkeutz J, Buckham J, Fischer R, Pöstges R, Boos J. Comparative in vitro studies on different 6-mercaptopurine formulations for use in children. Paediatr Perinat Drug Ther. 2007 ; 8 (1). 31-39
10. Balis F, Holcenberg JS, Poplack DG, et al. Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a Joint Children's Cancer Group and Pediatric Oncology Branch Study. Blood. 1998 ; 92 (10). 3569-3577
11. Lennard L. Therapeutic drug monitoring of cytotoxic drugs. Br J Clin Pharmacol. 2001 ; 52: 75S - 87S